Your browser is no longer supported. Please, upgrade your browser.
INFI Infinity Pharmaceuticals, Inc. daily Stock Chart
Infinity Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.71 Insider Own0.30% Shs Outstand60.51M Perf Week-5.66%
Market Cap116.20M Forward P/E- EPS next Y-0.56 Insider Trans0.00% Shs Float44.68M Perf Month88.68%
Income-41.30M PEG- EPS next Q-0.15 Inst Own49.00% Short Float0.41% Perf Quarter76.99%
Sales1.60M P/S72.63 EPS this Y-306.60% Inst Trans11.03% Short Ratio0.30 Perf Half Y127.27%
Book/sh-0.23 P/B- EPS next Y15.20% ROA-81.80% Target Price2.63 Perf Year63.93%
Cash/sh0.71 P/C2.81 EPS next 5Y- ROE824.00% 52W Range0.60 - 2.17 Perf YTD108.33%
Dividend- P/FCF- EPS past 5Y-18.20% ROI-592.30% 52W High-7.83% Beta2.28
Dividend %- Quick Ratio4.40 Sales past 5Y-55.00% Gross Margin39.80% 52W Low233.33% ATR0.17
Employees25 Current Ratio4.40 Sales Q/Q66.70% Oper. Margin- RSI (14)67.32 Volatility9.73% 11.61%
OptionableYes Debt/Eq- EPS Q/Q21.30% Profit Margin- Rel Volume0.72 Prev Close1.81
ShortableYes LT Debt/Eq- EarningsNov 09 AMC Payout- Avg Volume606.57K Price2.00
Recom2.40 SMA2031.97% SMA5054.43% SMA20087.06% Volume437,243 Change10.50%
Jun-27-19Initiated Oppenheimer Outperform
Jan-04-19Initiated B. Riley FBR Buy $3
Nov-12-18Downgrade Wells Fargo Outperform → Market Perform
Nov-12-18Downgrade JP Morgan Neutral → Underweight
Oct-12-17Upgrade Wells Fargo Market Perform → Outperform
Aug-10-16Reiterated Wedbush Neutral $1.25 → $1
Jun-15-16Downgrade Wells Fargo Outperform → Market Perform
Jun-15-16Downgrade RBC Capital Mkts Outperform → Sector Perform $12 → $2
Jun-15-16Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-15-16Downgrade Jefferies Buy → Hold
Jun-14-16Downgrade JP Morgan Overweight → Neutral
Jun-14-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-14-16Downgrade FBR Capital Outperform → Mkt Perform $15 → $2
Mar-02-16Initiated FBR Capital Outperform $15
Feb-25-16Reiterated Wedbush Neutral $9 → $8
Sep-21-15Upgrade Morgan Stanley Equal-Weight → Overweight
Aug-07-15Reiterated RBC Capital Mkts Outperform $18 → $15
May-07-15Initiated Deutsche Bank Buy $20
Oct-20-14Resumed Stifel Hold
Mar-06-13Reiterated Stifel Buy $39 → $50
Nov-17-20 09:22AM  
Nov-12-20 05:53AM  
Nov-09-20 06:35PM  
Nov-02-20 04:05PM  
Oct-28-20 12:33PM  
Oct-11-20 10:58AM  
Sep-30-20 09:15AM  
Sep-29-20 07:35AM  
Sep-04-20 08:05AM  
Aug-11-20 08:49AM  
Aug-10-20 03:30PM  
Jul-30-20 06:30PM  
Jul-23-20 07:35AM  
Jul-08-20 08:22AM  
Jun-10-20 03:46PM  
Jun-04-20 08:35AM  
May-12-20 12:48PM  
May-11-20 08:55AM  
May-04-20 07:35AM  
Apr-28-20 12:33PM  
Apr-20-20 07:59AM  
Apr-10-20 12:00PM  
Apr-07-20 07:35AM  
Apr-02-20 11:30AM  
Mar-26-20 06:07PM  
Mar-25-20 07:35AM  
Mar-17-20 01:49PM  
Mar-04-20 03:31PM  
Mar-03-20 05:35PM  
Feb-25-20 07:35AM  
Jan-23-20 08:34AM  
Jan-13-20 07:35AM  
Jan-09-20 09:00AM  
Dec-20-19 06:23PM  
Nov-09-19 10:24PM  
Oct-31-19 12:45PM  
Oct-30-19 06:25PM  
Oct-23-19 08:33AM  
Oct-08-19 10:02AM  
Sep-05-19 10:24AM  
Sep-04-19 08:32AM  
Sep-03-19 08:32AM  
Aug-29-19 09:31AM  
Aug-22-19 04:03PM  
Aug-03-19 07:50AM  
Jul-31-19 10:16AM  
Jul-30-19 08:55AM  
Jul-23-19 08:32AM  
Jun-24-19 08:33AM  
Jun-06-19 09:31AM  
May-29-19 08:32AM  
May-16-19 08:32AM  
May-15-19 12:54AM  
May-08-19 09:33AM  
May-07-19 07:25PM  
Apr-30-19 08:32AM  
Apr-13-19 09:30AM  
Apr-10-19 11:10AM  
Apr-02-19 08:32AM  
Mar-28-19 08:21AM  
Mar-25-19 09:00AM  
Mar-22-19 10:10PM  
Mar-18-19 11:26AM  
Mar-15-19 11:37AM  
Mar-14-19 09:50AM  
Mar-07-19 04:05PM  
Mar-06-19 07:32AM  
Feb-06-19 07:55AM  
Feb-04-19 08:32AM  
Jan-07-19 07:32AM  
Jan-03-19 04:05PM  
Dec-05-18 09:30AM  
Nov-13-18 07:26AM  
Nov-10-18 06:02AM  
Nov-09-18 08:35AM  
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. It offers IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol-Myers Squibb Company. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.